Baliopharm GmbH

https://www.baliopharm.com

Baliopharm AG is a biotechnology company focusing on the development of novel antibody-based therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer. Baliopharm’s antibody pipeline consisting of two selective TNF-R1 antagonists, Atrosab and Atrosimab and the bispecific anti-CD20/CD95 antibody construct, Novotarg. Baliopharm was founded in 2011 as a spin-off of Celonic AG, an internationally operating service provider in the area of contract development and manufacturing of biopharmaceuticals operating since 1998. Baliopharm AG is located in Basel (Switzerland). *

	Start	2012-01-30 established
	End	2016-07-21 renamed
	Group	Alvogen (Group)
	Today	Alvotech Germany GmbH
	Successor	Alvotech Germany GmbH
	Industry	therapeutic protein
	Industry 2	Atrosab
	Person	Herrmann, Andreas (Valerius Biopharma 201805 CEO + Founder before Alvotech + Celonic + Baliopharm + Synimmune + Cardion)

	Region	Jülich
	Country	Germany
	Street	13 Karl-Heinz-Beckurts-Str.
	City	52428 Jülich
	Tel	+49-2461-6210-855
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Promethera Biosciences S.A.. (4/10/18). "Press Release: Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates". Mont-Saint-Guibert & B

		Record changed: 2023-12-30

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]